The myotoxicity of statins

Current Opinion in Lipidology

Volumn 13, Issue 4, 2002, Pages 415-420

  Evans, Marc ^a   Rees, Alan ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Fibrate; HMG CoA reductase inhibitor; Myotoxicity; Rhabdomyolysis; Statin

Indexed keywords

CERIVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; STATIN;

CELL MEMBRANE; CELLULAR PARAMETERS; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; INCIDENCE; MEMBRANE STRUCTURE; MITOCHONDRION; MORTALITY; MUSCLE CELL; MUSCLE TOXICITY; PATHOGENESIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SAFETY; SKELETAL MUSCLE; TOXICITY;

ANTICHOLESTEREMIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUSCLE CELLS;

EID: 0036326155     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200208000-00009     Document Type: Review

References (48)

1. Relationship between baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular and all cause mortality and longevity
2. Coronary risk factors, endothelial function and atherosclerosis: A review
3. The pathogenesis of atehrosclerosis: A perspective for the 1990s
4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S)
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study
6. Reduction of LDL cholesterol by 25-60% in patients with primary hypercholesterolaemia by atorvastatin, a new HMG-CoA reductase inhibitor
7. Effects of pravastatin in patients with serum cholesterol levels between 5.2 to 7.8 mmol/l plus two additional atherosclerotic risk factors
8. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolaemia
9. Cholesterol lowering with statin drugs, risk of stroke and total mortality: An overview of randomized trials
10. Mevinolin: A highly potent competitive inhibitor of hydroxymetylglutaryl-co enzyme A reductase and a cholesterol lowering agent
11. Comparative tolerability of the HMG-CoA reductase inhibitors
12. Effect of pravastatin on cardiovascular effects in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial
13. The MRC/BHF Heart Protection Study: Preliminary results
14. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels
15. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin
16. Atorvastatin: An updated review of its pharmacological properties and use in dyslipidaemia
17. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
18. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations, (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
19. Clinical pharmacokinetics of cerivastatin
20. Electrical myotonia of rabbit skeletal muscles by HMG-Co A reductase inhibitors
21. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
22. Lovastatin decreases plasma and platelet cholesterol levels and normalizes elevated platelet fluidity and aggregation in hypercholesterolaemic patients
23. Reduction of plasma cholesterol by lovastatin in patients with severe hypercholesterolaemia
24. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin
25. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems
26. A disorder of muscle lipid metabolism and myoglobinuria: Absence of carnitine palmityl transferase
27. Rhabdomyolysis, acute renal failure and hepatopathy induced by lovostatin monotherapy
28. Effect of 3-hydroxy-3-methyl coenzyme A reductase inhibition on human gut mucosa
29. Mitochondria in neuromuscular disorders
30. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans
31. Polymyositis associated with simvastatin
32. Pravastatin associated inflammatory myopathy
33. In-vitro metabolism of simvastatin in humans identification of metabolizing enzyme systems and effect of the drug on hepatic P450s
34. Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers
35. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
36. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
37. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day
38. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin and simvastatin, using neonatal rat skeletal myocytes
39. Rhabdomyolysis after atorvastatin with gemfibrozil
40. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
41. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
42. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia
43. Plasma concentrations of lovastatin are increased by gemfibrozil but not by bezafibrate
44. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9
45. Role of peroxisome proliferator activated receptor in mediating effects of fibrates and fatty acids on gene expression
46. Combined treatment with specific ligands for PPARgamma: RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells
47. PPAR gamma and the treatment of insulin resistance
48. Rosiglitazone in combination with a statin: Effect on lipid profile in patients with type 2 diabetes